Julia Gregory

Julia Paige Gregory is Chairman & Chief Executive Officer at Isometry Advisors, Inc. since 2016.
Chairman at Nurix Therapeutics, Inc. since 2024.
Director at Iconic Therapeutics, Inc. since 2017.
Managing Director at M.M.
Dillon & Co. LLC since 2018.
Director at Spur Therapeutics Ltd. and Spinal Simplicity LLC.
Independent Director at Biohaven Ltd. since 2022.
Formerly President, Chief Executive Officer & Director at Five Prime Therapeutics, Inc. from 2009 to 2011.
President, Chief Executive Officer & Director at ContraFect Corp.
from 2015 to 2016.
Executive Chairman at Cavion, Inc. Director at Global Alliance for TB Drug Development from 2008 to 2014.
Director at Clinipace, Inc. from 2012 to 2014.
Independent Outside Director at Nxera Pharma Co., Ltd. from 2017 to 2020.
Non-Executive Director at Kuur Therapeutics Ltd. from 2018 to 2020.
Independent Director at IMV, Inc. from 2018 to 2023.
Independent Director at Biohaven Pharmaceutical Holding Co. Ltd. from 2017 to 2022.
Independent Non-Executive Director at Freeline Therapeutics Holdings Ltd. from 2020 to 2024.
CFO & Executive VP-Corporate Development at Lexicon Pharmaceuticals, Inc. from 2000 to 2008.
Head-Investment Banking & Life Sciences Practice at Punk Ziegel & Co. from 1996 to 2000.
Investment Banker at Dillon, Read & Co., Inc. from 1980 to 1996.
Education includes an MBA from The Wharton School of the University of Pennsylvania and undergraduate studies at Elliott School of International Affairs.